French start-up inHEART has raised €3.7m in a funding round led by Elaia. The company has developed a solution to address the issue of cardiac arrhythmia, one of the leading causes of sudden death. Current procedures for patients with arrhythmia are often suboptimal, lengthy, complex and costly. InHEART's solution involves using medical imaging to create a 3D model of a patient's heart. This digital twin allows cardiologists to better guide the operation, reducing the duration and failure rate of catheter ablation interventions by half.
InHEART was founded in 2016 by a team of cardiologists and engineers from the French National Institute of Health and Medical Research (INSERM). The start-up's technology has been tested on over 300 patients, with a success rate of over 90%. InHEART is positioning itself as the "Google Maps of cardiac interventions," with the aim of revolutionizing the treatment of cardiac arrhythmia.
Elaia is a venture capital firm that invests in early-stage start-ups in Europe. The firm has invested in a number of French start-ups, including Mirakl, Shift Technology, and Ledger.
InHEART's funding round will be used to accelerate the start-up's growth and expand its commercial offerings. The company plans to use the funds to develop its technology, expand its team and increase its presence in Europe and the United States.
InHEART's innovative solution to address the issue of cardiac arrhythmia has attracted €3.7m in funding from Elaia. The French start-up's technology has been tested on over 300 patients with a success rate of over 90%. The funding will be used to accelerate InHEART's growth and expand its commercial offerings, with the aim of revolutionizing the treatment of cardiac arrhythmia. Elaia's investment in InHEART is a testament to the potential of the start-up and its technology.
